Medical Innovation and the Battle Against Cancer

NET Patient Foundation attended the 13th Annual Lecture organised by the Medicines and Healthcare products Regulatory Agency.   This was an inspiring and thought provoking lecture delivered by Sir Harpal Kumar, former Chief Executive of Cancer Research UK, about...

Rare cancers: the landscape is changing

“Fourteen years ago, when I was first thrust as a new patient advocate into the world of rare cancers – following my son’s diagnosis of a brain tumor – I found it to be as lonely and terrifying a landscape as you could ever stumble into. At that time, I felt...

In Memory of Katharina Mellar

It is with a heavy heart that we have to announce that Katharina Mellar, the long-standing and tireless chairwoman of the Netzwerk NeT, passed away on the 23rd of August 2018. Her passing away is a great loss for all who knew her. Words fail us to describe it....

NET-02 Trial – First of its kind

NET-02:  A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouraciL (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated...